FINWIRES · TerminalLIVE
FINWIRES

Campbell's Faces Another Tough Year as Headwinds Deepen, RBC Says

By

Campbell's (CPB) is heading into another difficult year as the company's fiscal 2027 guidance points to persistent revenue and profit pressure, with weakness in snacks and elevated cost inflation expected to continue, RBC Capital Markets said Friday in a report.

Campbell's 36% cut to its quarterly dividend to $0.25 a share underscores the strain on the business and marks a reversal from management's reaffirmation of the payout in fiscal Q3, the report said. While the move frees up roughly $170 million annually for cash flow and debt payments, "the reversal in messaging will likely hurt confidence with income-oriented investors," RBC said.

The packaged-food company faces a similar degree of headwinds in fiscal 2027 as in Q4, with management expecting organic net sales to fall 2% to 4% and gross margins to decline 50 to 100 basis points for the year, RBC said.

The launch of a new enterprise-wide savings program targeting $500 million by fiscal 2030 shows Campbell's is taking steps to rebuild margins, with more than $100 million in savings expected in fiscal 2027, the report said.

RBC lowered its price target on Campbell's stock to $19 from $21 and maintained its sector-perform rating.

"We knew the path to recovery would not be straightforward, and we remain in wait-and-see mode amid what continues to be a reset period for the company, though we think management is doing the right things," the report said.

Price: $21.46, Change: $-0.67, Percent Change: -3.03%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT